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Rett syndrome (RTT) is an X-linked
neurodevelopmental disorder associated
with intellectual disabilities, which almost
exclusively affects females during early
childhood with an incidence of 1:10,000–
15,000 worldwide (Neul and Zoghbi,
2004). RTT is primarily caused by loss-
of-function mutations in methyl-CpG-
binding protein 2 (MECP2) (Amir et al.,
1999), the gene encoding MeCP2, a tran-
scriptional repressor that binds to methy-
lated CpG sites in promoter regions of
DNA (Lewis et al., 1992; Nan et al.,
1997). But to date, effective treatments
for RTT remain lacking, which makes
the identification of critical MeCP2 func-
tion of great importance to decipher the
molecular mechanisms of RTT pathogen-
esis. Recently, Baker et al. (2013) identi-
fied a highly conserved AT-hook domain
important for MeCP2 function and closely
related to clinical progressions observed in
RTT.
MeCP2 is an abundant chromatin-
associated nuclear protein with high
affinity binding to DNA containing
methyl-CpG throughout mammalian
genomes (Lewis et al., 1992; Nan et al.,
1997). MeCP2 contains two well-defined
functional domains: an N-terminal
methyl-CpG binding domain (MBD)
(Figure 1A), essential for its selective
binding to 5-methylcytosine; and a cen-
tral transcriptional repression domain
(TRD) (Figure 1A) that recruits the
transcriptional co-repressor Sin3A, his-
tone deacetylases (HDACs) (Jones et al.,
1998; Nan et al., 1998) and other
related chromatin-remodeling proteins
(Chahrour and Zoghbi, 2007) (Figure 1B).
In addition, a C-terminal domain (CTD)
(Figure 1A) facilitates DNA binding and
protein–protein interactions (Chandler
et al., 1999; Buschdorf and Stratling,
2004). Sporadic mutations in MECP2
cause 95% cases of RTT, among which
eight specific ones are the most common
and account for >65% of all individu-
als with RTT (R106W, R133C, T158M,
R168X, R255X, R270X, R294X, R306C)
(Figure 1A) (Calfa et al., 2011). Several
phenotype–genotype correlation studies
have contributed to gaining insight into
the role of MeCP2 in brain development.
In the February 28, 2013 issue of Cell,
Baker and colleagues describe the genera-
tion of two new mouse lines bearing either
a R270X or G273X truncation to mimic
male RTT patients with R270fs and G273fs
mutations, respectively. Characterizing
these mice, they discovered that G273X
mice exhibit a significantly delayed dis-
ease progression with a longer lifespan
compared to R270X mice, which led to
the hypothesis that the region between
R270 and G273 is important for MeCP2
function.
How is that just 3 amino acids,
have such significant consequences for
the progression and severity of the
mouse RTT-like phenotype? Using chro-
matin immunoprecipitation followed by
sequencing (ChIP-seq), the authors found
that both MeCP2-R270X and MeCP2-
G273X bind to DNA globally, very much
the same as wildtype MeCP2 does. Then,
they focused on the TRD (amino acids
207–310) where, these two mutations
locate, and found that both mutations dis-
rupt normal repressor activity of MeCP2.
By looking more closely at gene expression
over the course of disease, the authors dis-
covered a delay in misregulation of a small
subset of genes in G273X mice, although
most of those genes eventually become
misregulated as they do in R270X mice.
Despite that MeCP2’s repressor activity is
disrupted in G273X mice, these mice lived
longer and healthier thanMecp2 KO mice,
which suggests additional functions.
A highly conserved AT-hook domain
in MeCP2 that terminates at G273
(Figure 1A) answers the question. Adrian
Bird’s group had already described an
AT-hook domain in MeCP2, but its func-
tion was unclear (Klose et al., 2005)
(Figure 1A). AT-hooks are regions of
a protein that bind to AT-rich DNA.
MeCP2 requires an A/T-rich motif adja-
cent to methylated CpG dinucleotides
for efficient DNA binding (Klose et al.,
2005). Using an electrophoretic mobility
shift assay (EMSA), the authors discov-
ered a key difference between G273X
and R270X mutants: loss of function of
the second AT-hook domain impairs the
DNA-binding ability of the R270Xmutant,
indicating that amino acids 270–272 are
essential for the DNA-binding feature of
MeCP2. However, it is unclear if the probe
used in the EMSA contained A/T-rich
motives, which raises caution when con-
sidering this new MeCP2 feature as its
most critical in transcriptional regulation.
Prior work had shown the TRD-CTD
domain of MeCP2 is largely responsi-
ble for facilitating oligomerization of
nucleosomal arrays, as well as chromatin
compaction (Ghosh et al., 2010). Using an
in vitro assay of chromatin compaction,
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FIGURE 1 | MeCP2 structure and function in gene regulation and
chromatin remodeling. (A) A schematic diagram of MeCP2 structure with
functional domains and three AT-hook domains. Eight common MeCP2
mutations causing RTT and the two mutants discussed by Baker et al. (2013)
are indicated in black and red, respectively. Note that R270X is also one of
the most common mutations found in RTT individuals. (B) The function of
MeCP2 in transcription repression and chromatin compaction. As a
transcriptional repressor, MeCP2 recruits Sin3A, histone deacetylases
(HDACs), and some chromatin-remodeling proteins to silence target gene
transcription. Also, Baker et al. (2013) discovered that AT-hook clusters
facilitate MeCP2 to alter chromatin conformation by recruitment of ATRX to
PCH to maintain chromatin homeostasis.
Baker et al. (2013) show that MeCP2-
R270X does not compact chromatin as
efficiently as MeCP2-G273X does. These
results not only provide clear evidence
that this second AT-hook domain plays an
important role in manipulating chromatin
structure, but also explain the phenotypic
differences observed in G273X and R270X
mice. The authors propose that, after the
MBD of MeCP2 binds to methylated DNA
regions, the AT-hook clusters participate
in altering DNA conformation to aid in
chromatin packing (Figure 1B).
Furthermore, Baker and col-
leagues showed that the localization of
α-thalassemia/mental retardation syn-
drome X-linked protein (ATRX) to
pericentric heterochromatin (PCH) is a
distinguishing feature between G273X
and R270X. This is an intriguing finding
not only because ATRX syndrome shows
overlap with RTT, but also because ATRX
participates in chromatin remodeling,
associates with MeCP2, and disruption
of that interaction is thought to contribute
to intellectual disability (Nan et al., 2007).
The new findings by Baker et al. (2013)
strongly suggest that ATRX contributes
to the function of MeCP2 on chromatin
modification (Figure 1B). It would be
interesting to further explore the role of
ATRX in MeCP2 dysfunction not only in
RTT individuals, but also in other intel-
lectual disabilities associated with MECP2
mutations.
In summary, Baker et al. (2013) iden-
tified a novel AT-hook domain of MeCP2
that plays an important role in chromatin
organization, providing a new model
involving an additional protein partner,
which, incidentally, is also implicated
in a neurodevelopmental disorder asso-
ciated with intellectual disability. They
took advantage of the correlation between
mouse models and human individuals,
identified the pathogenesis of various
RTT-like phenotypes in novel mouse lines,
which increased our understanding of how
different MeCP2 functions are affected by
various disease-causing mutations. In this
regard, we very much share the hopes of
the authors that their discovery of a new
fundamental feature of MeCP2 can fur-
ther help in developing novel therapeutic
approaches for RTT and other intellec-
tual disabilities associated with MECP2
mutations.
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